Information  X 
Enter a valid email address
  Print      Mail a friend       More announcements

Wednesday 29 May, 2019

Minerva Neurosciences, Inc

Minerva Neurosciences to Present at Jefferies 2019 Global Healthcare Conference on June 4, 2019

Minerva Neurosciences to Present at Jefferies 2019 Global Healthcare Conference on June 4, 2019

WALTHAM, Mass., May 29, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will present at the Jefferies 2019 Global Healthcare Conference on June 4, 2019 at 3:00 p.m. Eastern Time.

The presentation will be webcast and accessible through the investor relations section of the Company’s web site, http://ir.minervaneurosciences.com.  

About Minerva Neurosciences

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat CNS diseases.  Minerva’s proprietary compounds include: roluperidone (MIN-101), in clinical development for schizophrenia; seltorexant (MIN-202 or JNJ-42847922), in clinical development for insomnia and major depressive disorder (MDD); MIN-117, in clinical development for MDD; and MIN-301, in pre-clinical development for Parkinson’s disease.  Minerva’s common stock is listed on the NASDAQ Global Market under the symbol “NERV.”  For more information, please visit www.minervaneurosciences.com

Contact:

William B. Boni
VP, Investor Relations/
Corp. Communications
Minerva Neurosciences, Inc.
(617) 600-7376


a d v e r t i s e m e n t